M
591.02
46.61 (8.56%)
| Penutupan Terdahulu | 544.41 |
| Buka | 552.42 |
| Jumlah Dagangan | 889,146 |
| Purata Dagangan (3B) | 342,995 |
| Modal Pasaran | 13,422,904,320 |
| Harga / Jualan (P/S) | 17.94 |
| Harga / Buku (P/B) | 21.74 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -123.38% |
| Margin Operasi (TTM) | -57.79% |
| EPS Cair (TTM) | -17.83 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 16.85% |
| Nisbah Semasa (MRQ) | 5.91 |
| Aliran Tunai Operasi (OCF TTM) | -395.31 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -274.11 M |
| Pulangan Atas Aset (ROA TTM) | -25.56% |
| Pulangan Atas Ekuiti (ROE TTM) | -50.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Madrigal Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.1
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.13 |
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 7.73% |
| % Dimiliki oleh Institusi | 108.28% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 900.00 (Piper Sandler, 52.28%) | Beli |
| Median | 630.00 (6.60%) | |
| Rendah | 445.00 (B of A Securities, -24.71%) | Pegang |
| Purata | 629.88 (6.58%) | |
| Jumlah | 7 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 526.40 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 19 Dec 2025 | 900.00 (52.28%) | Beli | 591.02 |
| 15 Oct 2025 | 540.00 (-8.63%) | Beli | 433.45 | |
| B. Riley Securities | 11 Dec 2025 | 670.00 (13.36%) | Beli | 571.33 |
| HC Wainwright & Co. | 21 Nov 2025 | 620.00 (4.90%) | Beli | 547.96 |
| 11 Nov 2025 | 568.00 (-3.89%) | Beli | 541.50 | |
| Oppenheimer | 20 Nov 2025 | 650.00 (9.98%) | Beli | 542.12 |
| 10 Oct 2025 | 590.00 (-0.17%) | Beli | 429.60 | |
| Truist Securities | 19 Nov 2025 | 640.00 (8.29%) | Beli | 555.60 |
| 15 Oct 2025 | 580.00 (-1.86%) | Beli | 433.45 | |
| Canaccord Genuity | 13 Nov 2025 | 587.00 (-0.68%) | Beli | 514.93 |
| Citizens | 05 Nov 2025 | 527.00 (-10.83%) | Beli | 475.87 |
| B of A Securities | 03 Nov 2025 | 445.00 (-24.71%) | Pegang | 412.35 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |